Mega Pharma Deal: Inside Rs 1.11 Lakh-Cr Sun Pharma-Organon acquisition—What's in it for investors?

Sun Pharmaceutical Industries on Monday announced its biggest-ever acquisition, agreeing to buy US-based Organon & Co. in an all-cash deal valued at $11.75 billion, including debt.

The transaction is the largest deal ever in Indian pharma and among the biggest overseas acquisitions by an Indian company.

Under the definitive agreement, Sun Pharma will acquire all outstanding shares of Organon for $14 per share. The deal has been approved by the boards of both companies and is expected to close in early 2027, subject to regulatory clearances and shareholder approval.

At an exchange rate of around Rs 94.22 per US dollar on April 27, 2026, Sun Pharma’s $11.75 billion Organon acquisition is valued at nearly Rs 1,10,703 crore.

The acquisition will be funded through a mix of internal cash and borrowings, making leverage and post-merger integration key areas for investors to watch.

Stock rises despite debt concerns

Normally, markets react cautiously to large debt-funded acquisitions because of concerns around borrowing, execution risks and valuation. But that did not happen this time.

Sun Pharma shares surged more than 8 per cent after the announcement and touched an intraday high of Rs 1,766.90 on the BSE. The stock was later trading around Rs 1,742, still up more than 7 per cent.

The rally added nearly Rs 27,400 crore to the company’s market capitalisation, showing investors largely welcomed the acquisition despite the large price tag.

Markets appear to believe this is a strategic expansion rather than an expensive gamble.

Why Organon matters

Organon was spun off from Merck & Co. in 2021 and has built businesses across women’s health, biosimilars and established medicines.

The company operates in around 140 countries and has more than 70 products in its portfolio. It also runs six manufacturing facilities across the European Union and emerging markets.

For 2025, Organon reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion. It carried debt of $8.6 billion and had cash reserves of $574 million.

The acquisition gives Sun Pharma immediate scale in key global markets and expands its business beyond its traditional strengths in generics and specialty medicines.

Following the deal, Sun Pharma is expected to enter the top 25 global pharmaceutical companies with combined revenues of $12.4 billion.

The company said it would also become a top-three player in global women’s health and the seventh-largest biosimilar company worldwide.

Management sees long-term value

Sun Pharma Executive Chairman Dilip Shanghvi said the transaction offers a major strategic opportunity.
“This transaction represents a significant opportunity. Organon’s portfolio, capabilities and global reach are highly complementary to our own,” he said.

Organon Executive Chair Carrie Cox said the all-cash transaction offers immediate value to shareholders and added that Sun Pharma is well-positioned to support Organon’s businesses globally.

Sun Pharma expects synergies of more than $350 million within two to four years of closing the transaction.

The combined entity will operate in 150 countries, with 18 markets each generating over $100 million in revenue.

One of India’s biggest overseas deals

The acquisition ranks among the largest overseas deals by Indian companies, alongside Tata Steel’s $12 billion takeover of Corus in 2007 and Bharti Airtel’s $10.7 billion acquisition of Zain Telecom’s African business in 2010.
For Sun Pharma, this follows earlier large deals such as the $4 billion acquisition of Ranbaxy Laboratories in 2014 and the takeover of Taro Pharmaceutical Industries.

This is more than a routine acquisition. With its biggest-ever deal, Sun Pharma is signalling a stronger ambition to become a diversified global pharmaceutical company rather than remain focused mainly on domestic leadership and US generics.

Deal math: Scale, margins and global footprint explained

• Combined revenue expected at nearly $12.4 billion, almost double from Organon’s $6.2 billion base
• EBITDA projected to rise to around $3.7 billion from nearly $1.8 billion standalone
• Free cash flow expected to remain strong at nearly $2.5 billion before financing
• Sun Pharma expected to become part of the top 25 global pharmaceutical companies
• Company likely to become the number one pharma player in four countries
• Revenue mix by geography: US 27 per cent, Emerging Markets 29 per cent, India 17 per cent, Europe and others 28 per cent
• Future revenue contribution: 51 per cent from established brands and branded generics, 27 per cent from innovative business, 15 per cent from generics, 6 per cent from biosimilars
• Organon has presence in 140 countries and world-class facilities for complex product manufacturing
• Acquisition opens access to South Korea market for Sun Pharma
• Deal also gives Sun a meaningful presence in China, a $150 billion-plus pharma market growing at 5–7 per cent annually
• Expected combined synergies of more than $350 million over the next 3–4 years
• Stable EBITDA margin expected at nearly 30 per cent
• Stronger push in women’s health with better licensing opportunities in developed markets
• New product opportunities expected across emerging markets
• Organon gets 55 per cent of revenue from established products
• Sun Pharma gets nearly 20 per cent of revenue from innovation-led business and plans to strengthen this further
• Biosimilar business gets a boost; Organon’s biosimilar revenue is around $700 million with 13 per cent growth over the last five years
• Transaction to be funded mainly through cash and partly through committed lines of credit
• Net Debt / EBITDA expected at 2.3x after the transaction
• Deal expected to close within 6–9 months, subject to regulatory and shareholder approvals
• Management described the acquisition as a transformative opportunity for Sun Pharma